Human Genome reiterated at market outperform by JMP

Human Genome Sciences Inc. was reiterated at a market outperform rating with a $15 price target by JMP Securities analyst Charles C. Duncan. The company's financial results were termed a non-event, with mixed results for fourth-quarter and fiscal year 2005. Revenues were better than expected but missed JMP's and consensus estimates on net loss. Shares of the Rockville, Md., biopharmaceutical company were down 3 cents, or 0.29%, at $10.49 on volume of 2,919,875 shares versus the three-month running average of 3,095,250 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.